Related Experiment Video
Updated: May 6, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Molecular mechanisms of hormone resistance of breast cancer
A M Scherbakov1, M A Krasil'nikov, N E Kushlinskii
1N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia. alex.scherbakov@gmail.com.
Abstract:
More than 70% malignant mammary tumors contain steroid hormone receptors; this suggests the possibility of hormone therapy in the majority of patients with breast cancer (BC). The main cause of inefficiency of hormone therapy in BC is hormone resistance (tumor resistance to hormonal cytostatics). Here we discuss the main mechanisms of hormone resistance of BC and the mechanisms underlying the formation of hormone resistance of the tumors are analyzed at the molecular level. The data on the signal pathways of estrogen receptors (ER), the key regulators of BC cell proliferation, are presented. The most important factors of BC hormone resistance are: high activity/expression of receptor tyrosine kinases; high activity of proteins regulating cell defense mechanisms (Akt PI3K, mTOR); changes in the activities of cell cycle regulator proteins (Myc, c-Fos, Cyclin D1). Our experiments have demonstrated that estrogen-independent BC cell growth is supported by VEGF/VEGFR2 and EGF/EGFR mitogenic signal pathways. Our data indicate that NF-kappaB transcription factor is directly involved in the regulation of hormone-resistant BC cell growth and survival, while NF-kappaB suppression determines cell sensitivity to apoptotic activity of antitumor compounds. On the whole, the results indicate good prospects of using EGFR, HER-2/neu, mTOR, VEGFR, PI3K/Akt molecular pathways as targets for BC therapy, including therapy for BC resistant forms.
Insights
Hormone resistance in breast cancer (BC) is a major challenge. Targeting specific molecular pathways like EGFR, mTOR, and VEGFR offers promising therapeutic strategies for hormone-resistant BC.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Over 70% of breast cancer (BC) tumors have steroid hormone receptors, indicating potential for hormone therapy.
- Hormone resistance is a primary reason for the ineffectiveness of hormone therapy in BC patients.
Purpose of the Study:
- To analyze the molecular mechanisms underlying hormone resistance in breast cancer.
- To identify key molecular pathways involved in hormone-resistant BC cell growth and survival.
Main Methods:
- Analysis of signal pathways of estrogen receptors (ER).
- Investigation of receptor tyrosine kinases, cell defense proteins (Akt PI3K, mTOR), and cell cycle regulators (Myc, c-Fos, Cyclin D1).
- Experimental validation of the role of VEGF/VEGFR2, EGF/EGFR, and NF-kappaB in estrogen-independent and hormone-resistant BC growth.
Main Results:
- High activity of receptor tyrosine kinases, Akt PI3K/mTOR, and cell cycle regulators (Myc, c-Fos, Cyclin D1) are key factors in BC hormone resistance.
- Estrogen-independent BC growth is driven by VEGF/VEGFR2 and EGF/EGFR signaling pathways.
- NF-kappaB transcription factor is crucial for hormone-resistant BC cell growth and survival; its suppression enhances sensitivity to antitumor agents.
Conclusions:
- Molecular pathways including EGFR, HER-2/neu, mTOR, VEGFR, and PI3K/Akt are promising therapeutic targets for BC.
- Targeting these pathways, including NF-kappaB, could overcome hormone resistance in BC therapy.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
Related Concept Videos
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...